Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Beijing InnoCare Pharma Raises $55 Million in Vivo-led Round

publication date: Feb 9, 2018

Beijing InnoCare Pharma raised $55 million in a funding round led by Vivo Capital and joined by CCB Capital. InnoCare is developing a portfolio of novel drugs for cancer and autoimmune diseases, using a combination of in-licensing and internal research. The company hopes its candidates, which target both China and global markets, will prove to be either first-in-class or best-in-class. InnoCare expects to release "landmark" clinical trial results this year. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital